US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Multiple Sclerosis · Relapsing Remitting Multiple Sclerosis · CTNM
Contineum Therapeutics
Contineum Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2017 Founded
59 Employees
Public company Type
CTNM · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2017
- Employees
- 59
- Programs
- 7
- Drugs
- 3
- Patents
- 2
Contineum Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Contineum Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Contineum Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist